Bringing doctors together

or

A free, private network for verified physicians

  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    ANGPTL4 Inhibition in Adults with Elevated Triglyceride Levels

    Nov 9, 2026DOI: 10.1056/nejmoa2612463Original ArticleNEJM

    Written by: Michelle L. O’Donoghue, M.D., M.P.H.Rebecca A. Juliano, Ph.D.B. Alexander Yi, M.D., Ph.D.Bernard Chung, M.B.A.Matilda Hughes, B.A.Daniel Gaudet, M.D., Ph.D.Harvey White, M.B., Ch.B., D.Sc.Gerald F. Watts, D.Sc., Ph.D., D.M.Julia Kuder, M.A.KyungAh Im, Ph.D.Yining Ye, Ph.D.Ethan J. Weiss, M.D.Joshua Lehrer-Graiwer, M.D., M.Phil.Marc S. Sabatine, M.D., M.P.H.

    Summary

    In a phase 2b trial involving adults with elevated triglyceride levels, MAR001, a monoclonal antibody against angiopoietin-like protein 4, significantly reduced fasting triglyceride levels at 12 weeks.
    TNThe New England Journal of Medicine

    The New England Journal of Medicine

    Official Account
    https://www.nejm.org/
    nejm